SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RO.SW, ROG.SW) announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide, in adults living with type 2 diabetes and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose of 24 mg achieved an HbA1c reduction of 2.65% from a baseline HbA1c of 8.1%. Also, 90% of patients in the 24 mg cohort reached an HbA1c level of ?6.5% and 62% achieved normoglycemia, HbA1c < 5.7%, restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.
Roche said it is advancing a broad late-stage development program for enicepatide, including two ongoing Phase III studies in chronic weight management and plans to initiate a Phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027.
At last close on SIX Swiss Exchange, Roche shares were trading at 364.80 Swiss francs, up 2.24%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
